Co-mutations in tumor immune microenvironment and immunotherapy
- PMID: 33942800
- PMCID: PMC8115994
- DOI: 10.1097/CM9.0000000000001455
Co-mutations in tumor immune microenvironment and immunotherapy
Conflict of interest statement
None.
References
-
- Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, et al. . Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 2015; 5:860–877. doi: 10.1158/2159-8290.CD-14-1236. - PMC - PubMed
-
- Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, et al. . Immunohistochemical loss of LKB1 is a biomarker for more aggressive biology in KRAS-mutant lung adenocarcinoma. Clin Cancer Res 2015; 21:2851–2860. doi: 10.1158/1078-0432.CCR-14-3112. - PubMed
-
- Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, et al. . STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res 2016; 76:999–1008. doi: 10.1158/0008-5472.CAN-15-1439. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
